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ICD-9 diabetes diagnosis (250.00 to 250.79) occurred
within one year of the patient’s transplant. We then used
a Kaplan-Meier-style non-parametric calculation to esti-
mate the average accumulated costs for patients with and
without NODM. RESULTS: Among the 4,515 trans-
plant recipients studied, 621 (13.7%) reported diabetes
diagnoses within the first year post-transplant. By the end
of the first post-transplant year, Medicare had paid
$35,288 for each non-diabetic recipient and an extra
$17,614 (P  0.001) for each of the NODM recipients.
By two years post-transplant, Medicare had paid an aver-
age $46,869 for each of the non-diabetic recipients and
an extra $26,032 for each of the NODM recipients (P 
0.001). CONCLUSIONS: Our 13.7% NODM exceeds
the 2% to 5% previously reported, and the extra
$26,032 is 55.5% above what Medicare paid for recipi-
ents without NODM. New immunosuppressives unasso-
ciated with NODM may generate substantial savings
worldwide.
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OBJECTIVES: The two major types of diabetes, Type I
and Type II diabetes, can have life-threatening complica-
tions, which often lead to significant adverse economic
consequences. This study investigates the extent to which
Type I and Type II diabetes impose significant financial
burdens on an employer METHODS: The data source is
a rich administrative claims database from a national,
Fortune 100 manufacturer. It includes all medical, phar-
maceutical, and disability claims for employees, spouses,
dependents, and retirees (n  100,000). The diabetes re-
search sample consists of individuals with at least two
medical and/or disability claims for diabetes or at least
one prescription drug claim for a hypoglycemic agent.
Resource utilization by diabetes patients, who are identi-
fied as either Type I or Type II diabetics, is contrasted
with that of matched samples from the employer’s overall
beneficiary population. RESULTS: Direct (medical and
pharmaceutical) and indirect (disability and sporadic ab-
senteeism) costs of Type I and Type II diabetes are ana-
lyzed. The total average per capita annual costs are
$2,612 for the Matched Type I Control sample compared
to $9,397 for Type I diabetics, and $3,432 for the
Matched Type II Control sample compared to $7,639 for
Type II diabetics. While Type I diabetics cost the em-
ployer more than Type II diabetics on average, the cost of
Type II diabetes patients, who were prescribed insulin,
exceeds the cost of Type I diabetes patients. Also, while
the costs of both types of diabetes are relatively high, less
than 50% of total medical costs for these patients are for
the treatment of diabetes or related co-morbid condi-
tions. CONCLUSIONS: Diabetes adds a significant fi-
nancial burden on the employer. The resources used by
both types of diabetics are substantial, not only for the
treatment of diabetes, but also for the treatment of re-
lated co-morbid conditions, as well as other conditions.
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OBJECTIVES: To conduct a pharmacoeconomic analysis
to estimate the potential cost avoidance due to reduced
rate of incidence of diabetes after weight-reduction ther-
apy in obese Chinese patients with impaired glucose tol-
erance (IGT). METHODS: The incidence of IGT-to-dia-
betes mellitus (DM) conversion of two hypothetical
cohorts of obese Chinese patients with IGT, either man-
aged with diet control (n  100) or diet control plus or-
listat (n  100), were projected over a two-year period.
The probabilities of IGT-to-DM progression in the or-
listat plus diet group and the diet only group were esti-
mated from a published study in a non-Chinese and a
westernized Chinese population, respectively. Direct medical
costs of management of type 2 diabetes were estimated
from a public budget perspective. RESULTS: The esti-
mated rates of IGT-to-DM conversion were 1.9% for the
orlistat plus diet group and 8% for the diet only group.
The total costs of DM management at the end of the first
and second years were estimated to be HK$8,187 and
HK$23,390 ($HK 7.8  $US 1) for the orlistat group. In
the diet only group, the costs of DM management were
HK$34,469 in year one and HK$100,123 in year two.
The cost avoidance associated with orlistat therapy were
calculated to be HK$26,282 and HK$75,092 per 100 pa-
tients at the end of the first and second years, respec-
tively. CONCLUSIONS: Results of the present study sug-
gest positive economic impacts of weight-reduction therapy
in a hypothetical Chinese population with IGT in the pre-
vention of type 2 diabetes.
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OBJECTIVES: Optimization of type 2 diabetes interven-
tion strategies in Germany based on stepwise prognoses
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of expected medical and economic outcomes in popula-
tion subgroups. METHODS: A published, editable dia-
betes model was used to assess the outcomes of different
degrees of secondary prevention measures for different
diabetes type 2 patient sub-groups in Germany. Clinical
data were derived from German diabetes quality of care
circles. Incremental cost-effectiveness ratios (ICERs) were
calculated as the differences of average lifetime cost di-
vided by the difference of average life expectancy. Opti-
mization was approximated by calculating ICERs for
stepwise modified prevention strategies, including screen-
ing and complication treatments for variable population
risk characteristics. RESULTS: Compared to the progno-
sis of overall life expectancy and cost consequences the
more refined stepwise approach generates a series of re-
sults for all combinations of intervention strategy and
population subgroup. At certain risk levels the ICER
based treatment recommendation may change if sub-
group prognosis is applied. But for all age groups of dia-
betes patients secondary prevention of complication is
the dominant variant. Medical outcomes and incremental
cost-effectiveness are improved by additional secondary
prevention measures except for patients with non-revers-
ible risks. The potential savings from improved preven-
tion amount to 10% of total expenditures for diabetes
care in Germany, i.e., DEM 3000 million. CONCLU-
SIONS: With the stepwise assessment of subgroup out-
comes a treatment optimization and optimal allocation of
diabetes management to patient subgroups is feasible. Us-
ing average data to calculate overall ICER for the total
diabetes population may ignore the best treatment strat-
egy in different population subgroups. Subgroup analysis
represents a helpful tool in the health economic evalua-
tion of diabetes treatment strategies when variable popu-
lation risk characteristics and baseline complications af-
fect the clinical and economic outcome.
PDB14
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OBJECTIVE: Evaluate the impact of a comprehensive di-
abetes disease management (DM) program on health care
costs, quality of life and patient satisfaction. METHODS:
Diabetes patients targeted by pharmacy claims were in-
vited to enroll in a voluntary payor-sponsored DM pro-
gram (n  2,178). Eligible non-enrollees were used for
the control group (n  6,396). Medical and pharmacy
claims were combined to determine health care costs.
Quality of life and patient satisfaction were also assessed,
via patient interview. The analysis timeframe encom-
passed two years prior and one year following program
initiation. RESULTS: Enrollees had higher direct health
care costs than non-enrollees. We were able to predict ac-
curately the medical spend in our control group in ab-
sence of intervention with standard time series analysis
within 4%. Following DM intervention, enrollees’ health
care spend was lower than their baseline spend and lower
than their projected spend ($116, $1,056). Con-
versely, health care spend increased in the non-enrollee
group from baseline ($714) (Table 1). Additionally, en-
rollee quality of life measures improved from baseline
and patient satisfaction with the DM program was high.
CONCLUSIONS: A comprehensive diabetes DM pro-
gram can lower health care cost and improve patient re-
ported quality of life while demonstrating consistently
high patient satisfaction.
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OBJECTIVES: Patient preferences for alternative treat-
ments may be affected by health status and experience
with the treatment. Randomized Clinical Trials (RCTs)
offer a unique opportunity to collect preference data
while controlling for patient experience. METHODS: Pa-
tients with Type II diabetes in a large US RCT answered a
series of stated preference (conjoint format) questions re-
garding attributes of alternative insulin therapies. All pa-
tients are insulin-naïve and take insulin as part of the
trial. Preference data is collected before the patient begins
insulin, after 3 months, and after 6 months of insulin
therapy. Insulin attributes include the frequency of insu-
lin injections, method of injection (syringe or pen), glu-
cose control and frequency of hypoglycemia. Personal
health data such as glucose control are collected at each
administration of the stated preference survey. RE-
SULTS: Preferences are analyzed in an ordered probit
panel model that controls for individual health status. In-
sulin administration attributes have the largest impor-
tance scores. The importance score of the insulin injec-
tion frequency attribute decreases during the later
observation points. While few patients experience night-
time hypoglycemia, this attribute is significant and has a
larger importance score than glucose control. CONCLU-
SIONS: Patient experience significantly affects patient
preferences and the derived pharmacoeconomic measures
and should be controlled in preference experiments. Re-
sults suggest that some insulin-naïve patients are more
averse to insulin injections before they begin insulin ther-
apy. Results also suggest that increased experience with
diabetes control measures during the trial affects treat-
ment preferences.
